Business Update13 May 2024, 01:15 pm
Biocon Ltd. Announces Semi-Exclusive Deal with Medix for Commercialization of Generic Saxenda® (Liraglutide) in Mexico
AI Summary
Biocon Limited, an innovation-led Indian biopharmaceutical company, has announced a semi-exclusive distribution and supply agreement with Medix, a Mexican specialty pharmaceutical company. Biocon will be responsible for obtaining regulatory approval, manufacturing, and supplying the drug product, while Medix will commercialize it in the Mexican market. The total addressable market opportunity for Liraglutide for obesity indication in Mexico is approximately US $37 million.
Key Highlights
- Biocon Limited signs semi-exclusive deal with Medix for commercialization of generic Saxenda® (Liraglutide) in Mexico
- Biocon will undertake responsibility for regulatory approval, manufacturing, and supply
- Medix to be responsible for commercialization
- Total addressable market opportunity for Liraglutide in Mexico is approximately US $37 million